C6 Modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption
- 1 July 1998
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 8 (13) , 1719-1724
- https://doi.org/10.1016/s0960-894x(98)00297-2
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Identification and SAR for a selective, nonpeptidyl thrombin inhibitorBioorganic & Medicinal Chemistry Letters, 1998
- L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitorBioorganic & Medicinal Chemistry Letters, 1998
- Small-molecule direct thrombin inhibitorsExpert Opinion on Therapeutic Patents, 1997
- L-373,890, An achiral, noncovalent, subnanomolar thrombin inhibitorBioorganic & Medicinal Chemistry Letters, 1997
- Potent Noncovalent Thrombin Inhibitors That Utilize the Unique Amino Acid d-Dicyclohexylalanine in the P3 Position. Implications on Oral Bioavailability and Antithrombotic EfficacyJournal of Medicinal Chemistry, 1997
- Challenges in the development of orally bioavailable thrombin active site inhibitorsBlood Coagulation & Fibrinolysis, 1995
- Design of Orally Active, Non-Peptidic Inhibitors of Human Leukocyte ElastaseJournal of Medicinal Chemistry, 1994
- Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogsJournal of Medicinal Chemistry, 1992
- Rat model of arterial thrombosis induced by ferric chlorideThrombosis Research, 1990
- Synthesis of selectively trifluoromethylated pyridine derivaties as potential antihypertensivesHelvetica Chimica Acta, 1988